Dexmedetomidine for Cesarean Section

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Cesarean Section, Affecting Fetus or Newborn
Interventions
DRUG

Dexmedetomidine

The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.

DRUG

Placebo

The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.

Trial Locations (1)

210029

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT02715154 - Dexmedetomidine for Cesarean Section | Biotech Hunter | Biotech Hunter